News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
309,208 Results
Type
Article (15048)
Company Profile (106)
Press Release (294046)
Multimedia
Podcasts (65)
Webinars (13)
Section
Business (97742)
Career Advice (472)
Deals (17505)
Drug Delivery (73)
Drug Development (40105)
Employer Resources (50)
FDA (7173)
Job Trends (6666)
News (166937)
Policy (15589)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (510)
Accelerated approval (13)
Adcomms (8)
Allergies (72)
Alliances (26792)
ALS (64)
Alzheimer's disease (568)
Antibody-drug conjugate (ADC) (134)
Approvals (7407)
Artificial intelligence (212)
Autoimmune disease (45)
Automation (12)
Bankruptcy (152)
Best Places to Work (4740)
BIOSECURE Act (9)
Biosimilars (132)
Biotechnology (42)
Bladder cancer (56)
Brain cancer (34)
Breast cancer (214)
Cancer (1605)
Cardiovascular disease (161)
Career advice (425)
Career pathing (13)
CAR-T (60)
CDC (6)
Cell therapy (189)
Cervical cancer (11)
Clinical research (35033)
Collaboration (831)
Compensation (336)
Complete response letters (34)
COVID-19 (891)
CRISPR (43)
C-suite (450)
Cystic fibrosis (63)
Data (2145)
Denatured (18)
Depression (55)
Diabetes (144)
Diagnostics (1872)
Digital health (11)
Diversity (2)
Diversity, equity & inclusion (14)
Drug discovery (124)
Drug pricing (115)
Drug shortages (12)
Duchenne muscular dystrophy (102)
Earnings (37279)
Editorial (20)
Employer branding (4)
Employer resources (45)
Events (43231)
Executive appointments (549)
FDA (8455)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (497)
Gene editing (74)
Generative AI (19)
Gene therapy (186)
GLP-1 (460)
Government (1530)
Grass and pollen (5)
Guidances (175)
Healthcare (4223)
HIV (11)
Huntington's disease (11)
IgA nephropathy (44)
Immunology and inflammation (68)
Immuno-oncology (16)
Indications (55)
Infectious disease (965)
Inflammatory bowel disease (81)
Inflation Reduction Act (8)
Influenza (31)
Intellectual property (123)
Interviews (60)
IPO (6804)
IRA (33)
Job creations (2136)
Job search strategy (381)
JPM (28)
Kidney cancer (9)
Labor market (28)
Layoffs (208)
Leadership (8)
Legal (3801)
Liver cancer (35)
Longevity (8)
Lung cancer (223)
Lymphoma (146)
Machine learning (13)
Management (17)
Manufacturing (459)
MASH (74)
Medical device (2307)
Medtech (2319)
Mergers & acquisitions (11194)
Metabolic disorders (475)
Multiple sclerosis (57)
NASH (14)
Neurodegenerative disease (96)
Neuropsychiatric disorders (39)
Neuroscience (1034)
Neurotech (1)
NextGen: Class of 2026 (1703)
Non-profit (640)
Now hiring (17)
Obesity (243)
Opinion (142)
Ovarian cancer (41)
Pain (113)
Pancreatic cancer (65)
Parkinson's disease (96)
Partnered (11)
Patents (235)
Patient recruitment (149)
Peanut (13)
People (31714)
Pharmaceutical (63)
Pharmacy benefit managers (19)
Phase 1 (9272)
Phase 2 (14892)
Phase 3 (13129)
Pipeline (2159)
Policy (136)
Postmarket research (1447)
Preclinical (3737)
Press Release (27)
Prostate cancer (103)
Psychedelics (16)
Radiopharmaceuticals (147)
Rare diseases (373)
Real estate (2935)
Recruiting (18)
Regulatory (12146)
Reports (17)
Research institute (618)
Resumes & cover letters (55)
Rett syndrome (5)
RNA editing (7)
RSV (22)
Schizophrenia (73)
Series A (91)
Series B (64)
Service/supplier (3)
Sickle cell disease (50)
Special edition (10)
Spinal muscular atrophy (83)
Sponsored (9)
Startups (1863)
State (2)
Stomach cancer (6)
Supply chain (51)
Tariffs (68)
The Weekly (45)
Vaccines (262)
Venture capital (35)
Weight loss (140)
Women's health (29)
Worklife (4)
Date
Last 7 days (204)
Last 30 days (760)
Last 365 days (11756)
2026 (1089)
2025 (12045)
2024 (14093)
2023 (16142)
2022 (22860)
2021 (23439)
2020 (22003)
2019 (16754)
2018 (13087)
2017 (15485)
2016 (14674)
2015 (17286)
2014 (13945)
2013 (11958)
2012 (12866)
2011 (13356)
2010 (12136)
Location
Africa (349)
Alabama (21)
Alaska (1)
Arizona (80)
Arkansas (3)
Asia (32012)
Australia (4097)
California (3509)
Canada (1644)
China (708)
Colorado (146)
Connecticut (141)
Delaware (127)
Europe (47391)
Florida (619)
Georgia (70)
Hawaii (1)
Idaho (12)
Illinois (365)
India (52)
Indiana (241)
Iowa (2)
Japan (350)
Kansas (81)
Kentucky (20)
Louisiana (5)
Maine (5)
Maryland (494)
Massachusetts (2865)
Michigan (49)
Minnesota (191)
Mississippi (1)
Missouri (36)
Montana (8)
Nebraska (7)
Nevada (22)
New Hampshire (9)
New Jersey (1570)
New Mexico (7)
New York (1040)
North Carolina (655)
North Dakota (2)
Northern California (1558)
Ohio (81)
Oklahoma (5)
Oregon (19)
Pennsylvania (780)
Puerto Rico (12)
Rhode Island (18)
South America (561)
South Carolina (10)
Southern California (1571)
Tennessee (53)
Texas (491)
United States (13948)
Utah (79)
Virginia (160)
Washington D.C. (42)
Washington State (259)
West Virginia (1)
Wisconsin (38)
Wyoming (1)
309,208 Results for "aslan pharmaceuticals pte ltd".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Faron Pharmaceuticals Ltd: Appointment of CFO
December 1, 2025
·
3 min read
Press Releases
Newly-formed Archerfish Precision Diagnostics Pte Ltd: Ushers a New Era in Advanced Diagnostics
March 6, 2025
·
5 min read
Press Releases
Faron Pharmaceuticals Ltd: Holding(s) in Company
December 5, 2025
·
3 min read
Press Releases
Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound
January 12, 2026
·
5 min read
Press Releases
Formosa Pharmaceuticals Announces Licensing Agreement with Samil Pharmaceuticals, Co., Ltd, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
January 12, 2026
·
3 min read
Biotech Bay
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
ASLAN Pharmaceuticals Ltd. announced today announced that it has entered into a definitive agreement for the purchase and sale of 5,000,000 of the Company’s American Depositary Shares, each ADS representing twenty-five ordinary shares, at an offering price of $1.00 per ADS in a registered direct offering.
March 12, 2024
·
6 min read
Biotech Bay
ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat
ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN) today announced it has received a favorable patentability opinion from the European Patent Office (EPO) acting as the International Examiner on a polymorph patent application for farudodstat which, if granted in the national stages, will extend effective patent protection for farudodstat until at least 2043.
February 29, 2024
·
5 min read
Biotech Bay
ASLAN Pharmaceuticals Announces Participation in January Investor Conferences - January 2, 2024
ASLAN Pharmaceuticals today announced its participation in upcoming conferences for January 2024.
January 2, 2024
·
1 min read
Business
ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics
ASLAN Pharmaceuticals announced that it has signed a new research collaboration agreement with its partner, Zenyaku Kogyo Co., Ltd., to establish a framework for a succession of research projects to explore the differentiation of eblasakimab’s mechanism of action versus biologic therapies for atopic dermatitis, dupilumab and lebrikizumab.
May 2, 2024
·
7 min read
Biotech Bay
ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs
ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today provided a business update and updates related to its programs, eblasakimab and farudodstat.
December 12, 2023
·
11 min read
1 of 30,921
Next
